All In Biotech

Drug Trial Radar · NCT07884461

The First-in-Human Study of GW906 Injection

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GW906 Injection in Chinese Healthy Subjects and Subjects With Mild Hypertension

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Mar 29, 2025

Primary completion

Aug 24, 2026

Study completion Aug 24, 2026

Sponsor

Sponsor type
Industry
First posted
Oct 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, single-dose, dose-escalation trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of GW906 in healthy subjects and subjects with mild hypertension, as well as to conduct an initial exploration of its clinical efficacy.

Conditions

  • Hypertension

Interventions

  • GW906 injectionDrug

    GW906 injection

  • PlaceboDrug

    Normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE) and serious adverse events (SAE)Time frame: Day 0 to Month 3

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.